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Objectives The purpose of this study was to assess cost-effectiveness and long-term clinical benefits of renal denervation in
resistant hypertensive patients.
Background Resistant hypertension affects 12% of hypertensive persons. In the Symplicity HTN-2 randomized controlled trial, catheter-
based renal denervation (RDN) lowered systolic blood pressure by 32 23mmHg from 178 18mmHg at baseline.
Methods A state-transition model was used to predict the effect of RDN and standard of care on 10-year and lifetime
probabilities of stroke, myocardial infarction, all coronary heart disease, heart failure, end-stage renal disease,
and median survival. We adopted a societal perspective and estimated an incremental cost-effectiveness ratio in
U.S. dollars per quality-adjusted life-year, both discounted at 3% per year. Robustness and uncertainty were eval-
uated using deterministic and probabilistic sensitivity analyses.
Results Renal denervation substantially reduced event probabilities (10-year/lifetime relative risks: stroke 0.70/0.83;
myocardial infarction 0.68/0.85; all coronary heart disease 0.78/0.90; heart failure 0.79/0.92; end-stage renal
disease 0.72/0.81). Median survival was 18.4 years for RDN versus 17.1 years for standard of care. The dis-
counted lifetime incremental cost-effectiveness ratio was $3,071 per quality-adjusted life-year. Findings were
relatively insensitive to variations in input parameters except for systolic blood pressure reduction, baseline sys-
tolic blood pressure, and effect duration. The 95% credible interval for incremental cost-effectiveness ratio was
cost-saving to $31,460 per quality-adjusted life-year.
Conclusions The model suggests that catheter-based renal denervation, over a wide range of assumptions, is a cost-effective
strategy for resistant hypertension that might result in lower cardiovascular morbidity and mortality. (J Am Coll
Cardiol 2012;60:1271–7) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.0292
oResistant hypertension is defined as elevated blood pressure
despite full doses of 3 antihypertensive agents, including a
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accepted July 31, 2012.diuretic. Hypertension is the most common risk factor for
the development of cardiovascular disease (CVD) (1,2) and
leads to long-term cardiovascular and renal consequences
that present a substantial burden to health care systems (2).
Resistant hypertension has been increasingly recognized as a
clinically important problem and might affect 13% of the
hypertensive population (3).
Recently, catheter-based renal denervation (RDN) treat-
ment has been shown to be a viable therapeutic approach for
resistant hypertension. This denervation reduces sympa-
thetic renal and central tonus (4) and arterial blood pressure
(5,6). The randomized controlled Symplicity HTN-2 trial
confirmed a systolic blood pressure (SBP) reduction of 32
3 mm Hg, compared with a change of 1  23 mm Hg
bserved for standard of care (SoC) (p  0.0001), from a
aseline SBP of 178  18 mm Hg (7). Beyond the surrogate
T
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lar events, nor costs, have been
evaluated as endpoints of clini-
cal studies.
Our aim was, therefore, to de-
velop a decision-analytic model to
predict long-term cardiovascular
consequences and to ultimately as-
sess the cost-effectiveness based on
the long-term clinical effectiveness
of this novel treatment option com-
pared to SoC alone.
Methods
We developed a state-transition
(Markov) model to project the
impact of treatment, defined to
be SoC plus catheter-based RDN
treatment with the Symplicity
RDN system (Medtronic Ardian
LLC, Mountain View, CA). We
used the model to compare RDN
plus the existing SoC—3 or more
antihypertensive medications—to
SoC alone. The model projects 7
clinical endpoints: stroke, myocar-
dial infarction (MI), all coronary
heart disease (CHD), heart failure
(HF), end-stage renal disease (ESRD), cardiovascular mortal-
ity, and all-cause mortality.
We utilized multivariate risk equations from large-scale
cohort studies, such as the Framingham Heart Study, to
compute transition probabilities. Values for other input
parameters were derived from systematic searches of litera-
ture catalogued in PubMed. Assumptions made in the base
case analysis were assessed in deterministic, structural, and
probabilistic sensitivity analyses.
Model structure and modeling framework. The Markov
model, which had a cycle length of 1 month and half-cycle
correction, included 34 health states to represent clinical
disease progression. The same model structure was used for
the 2 competing strategies. The model operates by taking the
reductions in SBP observed in the randomized controlled
trial (RCT) and applying associations, known from the
published literature, between SBP and clinical events to
estimate their number by type. The model follows a simu-
lated cohort with hypertension but no prior cardiovascular
events and tracks occurrence of stroke, MI, angina, HF,
ESRD, and death. As illustrated in Figure 1, cohort
members can reach more than one of these states. Patients
with angina can experience a subsequent MI or stroke (we
assumed a fixed proportion of stable vs. unstable angina).
Heart failure can follow long-standing hypertension or be
secondary to an MI. Patients with ESRD can subsequently
Abbreviations
and Acronyms
CHD  coronary heart
disease
CVD  cardiovascular
disease
ESRD  end-stage renal
disease
HDL  high-density
lipoprotein
HF  heart failure
ICER  incremental cost-
effectiveness ratio
MI  myocardial infarction
NICE  National Institute
for Clinical Excellence
PSA  probabilistic
sensitivity analysis
QALY  quality-adjusted
life-year
RCT  randomized
controlled trial
RD  risk difference
RDN  renal denervation
SBP  systolic blood
pressure
SoC  standard of carereach other endpoints. All patients status post another, snonfatal clinical event could experience a stroke. In the MI
and stroke states, disease-specific mortality rates are ad-
justed for 1 cycle to reflect increased mortality after the
event; similarly, the health-state utility weight (utility) for
MI is reduced for 6 months post-event.
All analyses were conducted using a life-time horizon
except where otherwise indicated. Our outcome measures
were clinical endpoint relative risks, median survival, and
incremental cost-effectiveness ratio (ICER), defined as the
incremental direct medical costs of treatment and conse-
quences in 2010 U.S. dollars divided by the incremental
health benefits expressed as quality-adjusted life-years
(QALYs). From a societal perspective, we discounted both
costs and health outcomes at 3% per year.
Input parameters. The estimated decrease in SBP after
RDN and other baseline patient characteristics were based
on results of the Symplicity HTN-2 trial (7); the baseline
characteristics of patients with true resistant hypertension
enrolled in this trial were similar to those in a registry of
patients meeting resistant hypertension criteria (8), except
for SBP: participants in HTN-2 had to have a baseline SBP
of 160 mm Hg per inclusion criteria. All other input
parameters were derived from systematic searches of the
PubMed literature (Online Appendix). Cardiovascular
event probabilities were obtained from the Framingham risk
equations, except for the incidence of MI for which the
PROCAM (Prospective Cardiovascular Münster Heart
Study) risk equation was used. The ESRD incidence was
estimated from the results of a more recent cohort study.
Mortality rates were based on the most recent published
estimates. Utilities were adjusted for different age groups by
application of a multiplicative factor (9). Cost estimates
were converted to 2010 U.S. dollars using the general
consumer price index for the U.S. (10,11). Table 1 lists the
key parameters (Online Appendix).
Model validation. The external validity of the model was
assessed in several ways. First, the predicted 10-year relative
risk of CHD for subjects with SBP 120 mm Hg were
compared to subjects with SBP of 180 mm Hg for 6
combinations of risk factors analyzed in the Seventh Report
of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (JNC7):
SBP, total cholesterol, high-density lipoprotein (HDL),
smoking, diabetes mellitus, and left ventricular hypertrophy
(Online Appendix) (12). For each combination of risk
factors, we compared our simulated relative risk to the
JNC7-reported relative risks. Second, the predicted MI and
stroke incidences were computed for a cohort with an
annual cardiovascular disease (CVD) risk of 2% and then
compared to the corresponding projections generated by the
U.K. National Institute for Clinical Excellence (NICE)
hypertension model, which was recently used to inform
guidelines for ambulatory blood pressure measurement (13).
hird, attempts were made to compare model projections to
vent rates reported for the placebo arms of several large-
cale hypertension RCTs (Online Appendix).
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October 2, 2012:1271–7 Effectiveness of Renal DenervationPatient characteristics. The modeled base case assesses the
mpact of RDN in a population similar to the Symplicity
TN-2 trial cohort (7). The mean baseline SBP was 178
m Hg (95% confidence interval: 175 to 182 mm Hg), and
he mean difference in SBP after 6 months of treatment was
32 mm Hg (38 to 25 mm Hg). On average, members
f the cohort were on 5 medications, had a mean age of 58
55 to 61) years, were 43% female, had a diabetes mellitus
revalence of 34%, and a current smoker prevalence of 16%.
ecause the Symplicity HTN-2 trial did not report lipid
evels, we used as a proxy 2005 to 2008 results from the
ational Health and Nutrition Examination Survey for
atients whose blood pressure remained uncontrolled de-
pite their use of 3 or more blood pressure medications (14).
ipid levels for this group were as follows: low-density
ipoprotein 108 (103 to 114) mg/dl, HDL 53 (51 to 55)
g/dl, and total cholesterol 199 (191 to 206) mg/dl (Online
ppendix). Unlike the National Health and Nutrition
xamination Survey subpopulation or the Symplicity
TN-2 cohort, however, our simulated cohort was assumed
ot to include subjects with prior cardiovascular events,
anifest CHD, or ESRD. We imposed this restriction on
he simulated cohort to ensure predictive validity of the
ultivariate risk equations employed in the model. In a
tructural sensitivity analysis, we explored the impact of this
ssumption. Patients in both cohorts were assumed to be
aintained on the antihypertensive medications from their
aseline.
Using our base case cohort, we computed 10-year and
ifetime probabilities of reaching one or several endpoints,
Figure 1 Schematic Depiction of the Model
Patients enter the hypertensive state and follow one of the depicted pathways thro
ESRD  end-stage renal disease; HF  heart failure; MI  myocardial infarction.ith each endpoint separately reported. All simulationswere conducted in TreeAge Pro (TreeAge Software, Wil-
liamstown, Massachusetts).
Analysis of uncertainty. We assessed uncertainty in mul-
tiple ways. First, we conducted one-way sensitivity analyses,
varying all clinical input parameters by at least 50% and
cost and utility parameters over defined ranges, as described
in Table 1 and in the Online Appendix. Second, we varied
the baseline SBP value (mean 178 mm Hg). Third, we
evaluated the following structural assumptions: 1) the
assumed persistence of the blood pressure reduction after
RDN (considering gradual effect size reduction over
time); 2) the hypothetical possibility that the RDN
procedure will have to be repeated to maintain treatment
effect; and 3) the possibility that discomfort after the
procedure substantially reduces utility for a short period
of time (6 days at utility value of 0, equating to death).
Fourth, we determined how large changes to individual
assumptions must be to exceed the $50,000 per QALY
willingness-to-pay threshold, which is sometimes used to
categorize interventions as having either good value
(ICER less than this threshold) or poor value (ICER in
excess of $50,000 per QALY) (15).
Finally, we conducted a probabilistic sensitivity analysis
(PSA). This involves randomly selecting values from known
or estimated distributions for all input parameters, running
the model, and repeating the process. We drew values from
54 distributions developed using primary data from the
Symplicity HTN-2 study, the literature, and expert opinion
(Online Appendix). The set of 5,000 results produced
characterizes the probability distributions of outcomes re-
e model until they eventually die.ugh thsulting from the uncertainty around the input parameters.
n; LVH
r
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Model validation. Model-predicted relative risks (SBP of
120 mm Hg vs. 180 mm Hg) were similar to those predicted
by the JNC7 model, except for the influence of increasing
total cholesterol and of diabetes. For these cases, our model
predicted more conservative relative risks associated with an
SBP of 120 mm Hg (12% risk difference; see Online
Appendix). In comparisons with the NICE model, our
model predicted an annual MI incidence of 0.39% and an
annual stroke incidence of 0.73% for a combined cohort of
men and women. The corresponding sex-specific inci-
dence rates predicted by the UK NICE model were
0.45% (males) and 0.26% (females) for MI, and 0.70%
(males) and 0.83% (females) for stroke. The results of
validation attempts against placebo arms of RCTs are
outlined in the Online Appendix, along with their
limitations. Clinical trial results were within the 95%
credible intervals and projections showed a tendency to
Key Input ParametersTable 1 Key Input Parameters
Parameter Base Case
Age 58 (45; 70) years
Sex 43 (0; 100) % female
SBP 178 (160; 200) mm Hg; RDN reduction: 32 (
Diabetes mellitus 34 (0; 100) %
Current smoker 16 (0; 100) %
LDL 3.54 (2.59; 5.17) mmol/l
HDL 1.40 (1.03; 1.55) mmol/l
Triglycerides 1.64 (0.56; 2.26) mmol/l
Stroke incidence Exponential (SBP, age, sex, CVD, LVH, DM, sm
CHD incidence Weibull (SBP, age, sex, menopausal status 
MI incidence Exponential (SBP, age, TG, HDL, LDL, DM, -
Primary HF incidence Exponential (SBP, age, sex, DM, LVH, cardiom
Secondary HF incidence 0.12% for AP, 0.18% post-MI, 23.1% in the fi
ESRD incidence Rate with HRs (SBP, DM)
Stroke mortality First 30 days 12.6%; RR post-MI 2.27; beyon
MI mortality 30 days: age-stratified; 1.5% (35 to 44), 3.4%
beyond: SBP stratified (1.3% to 3.8%) and
HF mortality First 30 days: 6%; beyond: 1.5% (months 2 t
ESRD mortality Age-stratified linear regression analysis
Stroke costs 30 days: $18,627 ($8,874 to $65,776); mon
MI costs 30 days: $21,127 ($8,260 to $48,288); ann
HF costs First year $14,532 ($7,071); second and foll
AP costs Stable: $3,674; unstable: $7,104 (both per y
ESRD costs DM patients: $76,851; all others $66,844 (b
Hypertension costs $868 (annually, $203 to $1,355)
RDN costs $12,500 (one-time material and procedure c
Stroke utility 0.63 (0.26 to 0.92)
MI utility First 6 months: 0.76 (0.5 to 0.87); beyond: 0
HF utility 0.71 (0.43 to 0.84)
AP utility Stable: 0.84 (0.62 to 0.90); unstable: 0.74 (0
ESRD utility 0.63 (0.46 to 0.84)
Hypertension utility 0.96 (0.79 to 0.98)
AF atrial fibrillation; AP angina pectoris; CHD coronary heart disease; CVD cardiovascular
HDL high-density lipoprotein; HF heart failure; HR hazard ratio; LDL low-density lipoprotei
isk; SBP  systolic blood pressure; TC  total cholesterol; TG  triglycerides.rather over-predict than under-predict.Base case results. The model predicted that RDN would
reduce each of the clinical event risks as compared to SoC.
The smallest 10-year relative risks were obtained for MI,
stroke, and ESRD (0.68, 0.70, and 0.72, respectively)
whereas CHD and HF risk reductions were less substantial
(0.78 and 0.79, respectively). Over 10 years, RDN reduced
cardiovascular mortality by 30% and all-cause mortality by
15%. Over lifetime, risk reductions were less pronounced
(Table 2). Reduced clinical event risks increased median
survival from 17.07 to 18.37 years (an increment of 1.30
years) and quality-adjusted life expectancy from 12.07 to
13.17 QALYs (undiscounted: an additional 1.10 QALYs).
Although RDN over lifetime reduced undiscounted costs by
$1,769, it increased discounted costs by $2,013. This
difference reflects the fact that RDN costs are incurred
upfront while the resulting savings take place over a lifetime
and hence are reduced when discounting procedures are
applied. The discounted lifetime ICERs for RDN were
ric Value (Range) or Survival Model (Covariates)
) mm Hg
, AF)
DL, TG , DM, smoking, medications, alcohol)
oking)
, vital capacity, heart rate, CHD, valve disease)
days
2.3 on background mortality; RR post-MI 2.99; post-HF 2.189
to 54), 7.3% (55 to 64), 15.9% (65 to 74) 29.5% (75);
djusted: RR 1.28 (60 to 69); 2.46 (70)
0.7% (13 months)
to 12: $30,801 ($8,121 to $65,695); second year: $27,900 ($13,922 to $65,695)
intenance: $3,750 ($0 to $10,504)
years $5,212 ($3,958 to $10,904)
2,746 to $6,470 and $4,356 to $9,852)
r year; $53,935 to $89,882 and $45,159 to $79,350)
,000 to $15,000)
.67 to 0.94)
0.83)
e; DM diabetes mellitus; ESRD end-stage renal disease; -GT gamma-glutamyltransferase;
left ventricular hypertrophy; MImyocardial infarction; RDN renal denervation; RR relativeNume
15; 40
oking
, TC, H
GT, sm
egaly
rst 30
d: HR
(45
age-a
o 12);
ths 2
ual ma
owing
ear, $
oth pe
ost; $8
.88 (0
.53 to
diseas$2,715 per life-year gained and $3,071 per QALY.
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October 2, 2012:1271–7 Effectiveness of Renal DenervationUncertainty analyses. Model projections were relatively
nsensitive to plausible modifications of most input assump-
ions. The only input parameters that had a significant
mpact on the ICER were RDN-associated SBP reduction
effect size), baseline SBP, and costs for RDN therapy. In
hreshold analyses, the ICER exceeded the $50,000 per
ALY willingness-to-pay threshold only when the SBP
eduction after RDN was assumed to be no more than 11.1
m Hg, substantially less than what has been observed in
linical trials (99% confidence interval: 22.8 to 40.5 mm Hg
eduction). When baseline SBP was varied between 160 and
00 mm Hg, RDN was cost-saving between 160 and 172
m Hg, and then gradually increased to $6,305 per QALY
t 200 mm Hg. Structural sensitivity analyses assessed the
ffect of several additional scenarios. Under the hypothetical
ssumption that the treatment effect would decrease by 1
m Hg annually, the projected ICER increased to approx-
mately $13,300 per QALY. Threshold analysis revealed
hat SBP reduction would need to decrease by3.0 mm Hg
per year for ICER to exceed the $50,000 per QALY
willingness-to-pay threshold. Assuming as many as 3 repeat
procedures, 1 every 10 years, increased the ICER to $19,869
per QALY. Combinations of effect size reduction and
repeat procedures are shown as 2-way sensitivity analyses in
the Online Appendix. Assuming that patient utility is zero
for the 6 days after the RDN procedure increased the ICER
minimally to $3,135 per QALY. When modeling a cohort
with prior cardiovascular events as per the baseline charac-
teristics of the Symplicity HTN-2 study, the quality-
adjusted life expectancy increased by 0.46 QALYs while
costs increased by $1,270, resulting in an ICER of $2,732
per QALY (all values discounted). (See the Online Appendix for
dditional sensitivity analyses.)
The PSA for the examined cohort yielded a 95% credi-
ility interval that ranged from cost saving to $31,460 per
ALY. In all simulations, RDN improved health (i.e.,
ncremental QALYs were 0), and in 21.1% of the simu-
ations, RDN also decreased costs (i.e., was cost-saving).
inety-seven percent of the simulation results were below a
Base Case ResultsTable 2 Base Case Results
Base Case
10-Year Time Horizon
%SoC %RDN RD
Stroke 11.6% 8.2% 3.4%
MI 9.6% 6.5% 3.1%
CHD 24.8% 19.4% 5.4%
HF 5.4% 4.3% 1.1%
ESRD 2.9% 2.1% 0.8%
CV mortality 12.5% 8.7% 3.8%
All-cause mortality 23.0% 19.5% 3.5%
Median survival
QALYs
Discounted ICER
CV  cardiovascular; ICER  incremental cost-effectiveness ratio; RD  risk difference; QALY illingness-to-pay threshold of $30,000 per QALY, mean- tng that the PSA results indicate there is a 97% chance that
he ICER is $30,000 per QALY in the examined cohort.
he results also indicate that there was a 99.6% probability
hat the ICER is less than the $50,000 per QALY thresh-
ld. (See Online Appendix for graphical PSA results.)
iscussion
ur results indicate that RDN might be cost-effective when
ompared to other, well-accepted medical treatments with
n incremental cost-effectiveness ratio that is markedly
elow the commonly accepted threshold of $50,000 per
ALY. Moreover, there might be an approximately 1 in 5
hance that RDN is cost-saving in the investigated cohort.
lthough RDN therapy represents an additional cost at
ime of treatment, it seems to offer great value over time.
According to our findings, RDN for resistant hyperten-
ion substantially reduces CVD and ESRD and increases
urvival. Cardiovascular endpoints decreased by 21% to 32%
ver 10 years and between 8% and 17% over lifetime. The
ore modest risk reductions observed over a lifetime might
eflect the late-in-life contribution of events that were
elayed by RDN but not fully prevented. These events may
eflect the impact of other risk factors (e.g., diabetes,
yslipidemia, or smoking) that blood pressure reduction
oes not address. Because of these contributions, relative
isk may differ across groups with different combinations of
hese and other risk factors. The JNC7 risk predictions,
sed in this paper to validate our model, also indicate that
elative risks vary across groups with different cardiovascular
isk factors.
External validation demonstrated that the simulation
odel-predicted relative risks for cardiovascular outcomes
SBP 120 mm Hg vs. 180 mm Hg) were similar to or
lightly more conservative than the JNC7/Framingham-
ased predictions for 6 different hypothetical cohorts. In
ddition, projections by our model were similar to estimates
rom the NICE hypertension model except for stroke, the
isk of which our model slightly under-predicted. Uncer-
Lifetime Horizon
RR %SoC %RDN RD RR
0.70 31.9% 26.4% 5.5% 0.83
0.68 31.0% 26.2% 4.7% 0.85
0.78 55.3% 49.6% 5.7% 0.90
0.79 14.1% 13.0% 1.1% 0.92
0.72 5.5% 4.4% 1.1% 0.81
0.70
0.85
17.07 18.37 1.30 1.08
12.07 13.17 1.10 1.09
$3,071/QALY
djusted life-year; SoC  standard of care; other abbreviations as in Table 1.ainty analysis likewise suggests our findings are robust as
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model projections.
As with most models evaluating long-term treatment
effects, assumptions had to be made about the persistence of
the therapeutic benefit. The Symplicity HTN-2 random-
ized controlled trial data reveal an initial reduction of 20
mm Hg 1 month after the RDN procedure, and of 32 mm
Hg 6 months post-procedure (7). At the American College
of Cardiology 61st Annual Scientific Session, the 12-month
follow-up data from the HTN-2 trial and the 36-month
data from the HTN-1 study were presented that indicate a
sustained SBP reduction of 28 mm Hg and 33 mm Hg,
respectively (16,17). Our base case assumption that this
reduction persists indefinitely has not yet been confirmed,
but seems reasonable given the observed growth in the
treatment effect over time and literature suggesting that the
effect of RDN is likely to persist or possibly even grow (18).
We also addressed this assumption in comprehensive sensitiv-
ity analyses, which showed that RDN remains cost-effective
across a wide range of assumptions, including a fade-out of
effect size of 2 mm Hg per year, or up to 3 repeat procedures
with 5 years between each of them. Moreover, our model only
reflects the beneficial impact of SBP reduction on cardiovas-
cular and ESRD morbidity and mortality. Renal denervation is
under investigation in other clinical settings, including in-
creased insulin sensitivity (19), a further decreased risk for
chronic kidney disease (20), and amelioration or stabilization of
HF (21) and of sleep apnea (22); RDN is investigational in
some of these comorbid subgroups and several trials are
currently recruiting patients (Online Appendix). Omitting
these potentially beneficial effects means that our results may
understate the favorability of RDN’s clinical effectiveness, and
therefore also its economic effectiveness.
Our model differs from other recently published decision-
analytic hypertension models (13,23) in some important
respects. First, it includes ESRD as an additional relevant
endpoint for costs and life expectancy. ESRD was not an
endpoint, for example, in the recently published hyperten-
sion model used for policy-making by NICE (13). Second,
our model characterizes possible sequelae of CVD, includ-
ing acute-phase and secondary events (23). Third, because
our model uses the Framingham and other multivariate risk
equations, differences in event probabilities between cohorts
with different risk profiles can be modeled more accurately
by explicitly taking into account relevant clinical input
parameters such as lipid levels or underlying comorbid
conditions such as atrial fibrillation or cardiomegaly/
ventricular hypertrophy (13,23).
Despite this advantage, using results from an observational
study rather than from an interventional study may reduce the
magnitude of projected clinical benefits and hence the fa-
vorability of our cost-effectiveness estimates. Studies such as
the Framingham Heart Study used here often use multivariate
analyses to isolate the independent contribution of each factor
to changes in risk while controlling for the others. For example,
because the multivariate risk equation for MI suggests thatLDL, HDL, and triglyceride levels strongly influence MI risk,
controlling for these factors might reduce the residual predicted
contribution of blood pressure to MI risk due to confounding,
as some cardiovascular risk factors might be associated with
each other.
In contrast, estimating the association between blood pres-
sure and risk of reaching one of the clinical endpoints with
evidence from interventional studies might yield a stronger
estimate of this relationship, in part because these studies often
use univariate regression analysis to estimate association mea-
sures. However, even among interventional studies of antihy-
pertensive therapies, estimates of the relationship between
blood pressure and the risk of reaching an endpoint vary (e.g.,
HF) (24). Finally, compared to observational studies, interven-
tional studies have relatively limited follow-up (up to 5.5 years)
(25) and, in some cases, a small sample size.
Study limitations. First, our model, by definition, repre-
sents CVD using a limited number of health states and
transitions that may not always reflect the full spectrum of
possible pathways of disease progression. Second, our model
assumptions are based on office-based SBP measurements,
which may imply larger SBP reductions than would be
implied by ambulatory measurements. However, because
most SBP measurements in the literature are based on office
measurements, and the multivariate risk models use office-
based SBP, this limitation is typical. Third, subjects in our
dataset were mostly Caucasian. Therefore, these data may
not be representative of the entire U.S. population. It is
known, for example, that hypertension contributes about
15% to the difference in life expectancy between African
Americans and Caucasians (26). Future clinical trials are
likely to address this issue. Results of probabilistic sensitivity
analyses for cohorts other than the one investigated here
might differ in their proportions that are cost saving or
cost-effective at given willingness-to-pay thresholds.
Fourth, to facilitate implementation, we did not build into
the model all possible combinations of primary disease and
subsequent disease development. For example, the model
accounts for the possibility that angina may be followed by
MI or stroke, but not ESRD. The model included those
pathways with the highest probability and hence reasonably
approximates the disease process, but by omitting some
pathways, it may understate the aggregate impact of ele-
vated blood pressure. Fifth, because the current experience
with RDN is relatively modest, adverse events that might
occur after RDN have not been identified or included in
this study except for a sensitivity analysis, which consid-
ered short-term reduced quality of life after the procedure
(Online Appendix). Sixth, our model assumes the same
health-related quality of life in the initial hypertension state
for both RDN and SoC groups, although certain symptoms
such as headaches or anxiety might improve in the former
group after denervation treatment and resulting SBP de-
crease. Because our model effectively assumes that these
potential improvements have no effect on quality of life, it
conservatively understates aggregate societal benefits and,
s1277JACC Vol. 60, No. 14, 2012 Geisler et al.
October 2, 2012:1271–7 Effectiveness of Renal Denervationtherefore, understates the favorability of the ICER. Sev-
enth, in the probabilistic sensitivity analysis we were unable
to account for covariance between the input parameters as
no such data were available to us. Finally, our analysis is
based on the clinical findings of the Symplicity HTN-2
study, and assumes cost and effect size of the Symplicity
system. Results are not readily transferable to other RDN
systems. The Symplicity system is currently approved in
Europe and other markets, but is investigational in the
United States (NCT01418261).
Conclusions
Our results suggest that catheter-based RDN therapy is a
cost-effective treatment strategy for resistant hypertension
that might be more than an order of magnitude below the
recognized threshold of $50,000 per QALY, depending on
the durability of the treatment effect. Renal denervation
might also be associated with substantial reductions in
cardiovascular morbidity and mortality.
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APPENDIX
For additional information on literature searches, methodology, results,
figures, and tables, please see the online version of this article.
